

Clinical trials of aspart

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
aspart + basal vs continuous infusion			
Raskin , 2003 n=NA follow-up:	multiple daily injection bolus insulin aspart and basal NPH insulin versus continuous subcutaneous insulin infusion	-	
biphasic insulin aspart 30 vs insulin detemir			
Lundby , 2009 n=NA follow-up:	biphasic insulin aspart 30 versus insulin detemir before bedtime	-	
insulin aspart at mealtimes vs NPH insulin once daily			
Gram , 2011 n=NA follow-up:	insulin aspart at mealtimes versus NPH insulin once daily at bedtime	-	
premix aspart70/30 twice daily vs once daily insulin glargine			
INITIATE (Raskin) DOUBLON , 2008 n=NA follow-up:	biphasic insulin aspart 70/30 (BIAsp 70/30, prebreakfast and presupper) versus once-daily insulin glargine	insulin-naive patients with HbA1c values 8.0% on 1,000 mg/day metformin alone or in combination with other OADs	Parallel groups
aspart vs premix			
Bretzel , 2004 n=NA follow-up:	preprandial insulin aspart versus human premix (70% NPH/30% regular) insulin	-	

More details and results :

- insulin therapy for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q548>

References

Raskin, 2003:

Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein RL, McGill JB, Peterson GE, Mudaliar SR, Reinhardt RR Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. *Diabetes Care* 2003;26:2598-603 [[12941725](#)]

Lundby, 2009:

Lundby Christensen L, Almdal T, Boesgaard T, Breum L, Dunn E, Gade-Rasmussen B, Gluud C, Hedetoft C, Jarloev A, Jensen T, Krarup T, Johansen LB, Lund SS, Madsbad S, Mathiesen E, Moelvig J, Nielsen F, Perrild H, Pedersen O, Roeder M, Sneppen SB, Snorgaard Study rationale and design of the CIMT trial: the Copenhagen Insulin and Metformin Therapy trial. *Diabetes Obes Metab* 2009;11:315-22. [[19267709](#)] [10.1111/j.1463-1326.2008.00959.x](#)

Gram, 2011:

Gram J, Henriksen JE, Grodum E, Juhl H, Hansen TB, Christiansen C, Yderstrøde K, Gjøessing H, Hansen HM, Vestergaard V, Hangaard J, Beck-Nielsen H, Pharmacological treatment of the pathogenetic defects in type 2 diabetes: the randomized multicenter South Danish Diabetes Study. *Diabetes Care* 2011;34:27-33. [[20929990](#)] [10.2337/dc10-0531](#)

INITIATE (Raskin) DOUBLON, 2008:

Goodall G, Jendle JH, Valentine WJ, Munro V, Brandt AB, Ray JA, Roze S, Foos V, Palmer AJ, Biphasic insulin aspart 70/30 vs. insulin glargine in insulin nave type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting. *Int J Clin Pract* 2008;62:869-76. [[18479280](#)] [10.1111/j.1742-1241.2008.01766.x](#)

Moses AC, Raskin P, Khutoryansky N, Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine. *Diabet Med* 2008;25:200-5. [[18290862](#)] [10.1111/j.1464-5491.2008.02384.x](#)

Ray JA, Valentine WJ, Roze S, Nicklasson L, Cobden D, Raskin P, Garber A, Palmer AJ, Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US. *Diabetes Obes Metab* 2007;9:103-13. [[17199725](#)] [10.1111/j.1463-1326.2006.00581.x](#)

Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. *Diabetes Care* 2005 Feb;28:260-5 [[15677776](#)]

Bretzel, 2004:

Bretzel RG, Arnolds S, Medding J, Linn T, A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. *Diabetes Care* 2004;27:1023-7. [[15111514](#)]